Advertisement

Oncology / Hematology General

Evaluating The Liposomal Doxorubicin Supercharge-Containing Front-Line Treatment

Sep 07, 2022

For a study, researchers sought to determine how interim fluorodeoxyglucose positron emission tomography (interim-FDG-PET) responses in high-risk diffuse large B-cell lymphoma (DLBCL) or classic Hodgk...

Chronic Lymphocytic Leukemia Metabolic Alterations in The Lymph Node Microenvironment

Sep 07, 2022

The characteristic of both cancer and cell division is altered metabolism. For example, chronic lymphocytic leukemia (CLL) cells move between lymph nodes (LNs) and peripheral blood (PB), where they ar...

In Allogeneic T-ALL Cells, Cytosine Base Editing Allows Quadruple Editing

Sep 07, 2022

Allogeneic chimeric antigen receptor T-cell (CART) treatments need several gene alterations to be therapeutically feasible. Unfortunately, the majority of allogeneic CARTs were produced utilizing gene...

Restoring Telomere Length in Dyskeratosis Congenita Through TINF2 Editing

Sep 07, 2022

Telomere shortening and the hereditary bone marrow (BM) failure syndrome dyskeratosis congenita (DC) are two conditions brought on by mutations in the TINF2 gene, which produces the shelterin protein ...

First-line Treatment with Daratumumab in Patients Newly Diagnosed with Myeloma Shows Cost Effectiveness

Sep 07, 2022

For patients with newly diagnosed multiple myeloma (NDMM) who are transplant candidates, triplet regimens like thalidomide, bortezomib, and dexamethasone (VTd) or lenalidomide, bortezomib, and dexamet...

Pediatric Bone Marrow Failure Caused by Inherited Factors

Sep 06, 2022

A wide range of diseases known as inherited bone marrow (BM) failure syndromes is defined by BM failure, frequently in conjunction with more than or around 1 extrahematopoietic abnormality. The pediat...

DDX41 Germline Mutations and Prognosis in Intensively Treated Acute Myeloid Leukemia Patients

Sep 06, 2022

The most frequent genetic susceptibility to myelodysplastic syndrome and acute myeloid leukemia (AML) is DDX41 germline mutations (DDX41MutGL). DDX41MutGL myeloid cancers may be regarded as a separate...

DDX41 Variants Associated with Myeloid Neoplasms in the Germline

Sep 06, 2022

The most prevalent mutations predisposing to acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) in adults are DDX41 variations. However, the causal variant (CV) landscape and clinical spectru...

Treatment Outcomes in Severe Combined Immunodeficiency in ADA-Deficient Patients

Sep 06, 2022

Approximately ∼13% of instances of severe combined immune deficiency (SCID) are due to adenosine deaminase (ADA) deficiency. Gene therapy (GT), hematopoietic cell transplantation (HCT), and enzyme r...

Breast Cancer Patients Still Face Challenges in Treating ETR

Sep 05, 2022

For a study, researchers sought to identify the molecular processes causing Endocrine therapy resistance (ETR) using a thorough genomic investigation of breast tumors. Pre-treatment and post-treatment...

Diabetes and Prostate Cancer: The Impact of Mutations in PIK3R1

Sep 05, 2022

For a study, researchers sought to understand that patients either had their tumors profiled using The Cancer Genome Atlas or had their tumors sequenced using the MSK-IMPACT clinical assay to screen f...

Synovial Sarcoma Lacking Malic Enzyme 1 Are More Sensitive to Ferroptosis Induction by ACXT-3010

Sep 05, 2022

For a study, researchers sought to analyze synovial sarcoma (SS) metabolism and determine how SS redox equilibrium is affected by malic enzyme 1 deficiency. Clinical SS tissues, SS cell lines, and tum...

Spatial and Transcriptomic Analysis of Perineural Invasion in Oral Cancer

Sep 05, 2022

For a study, researchers looked at the spatial and transcriptomic characteristics of perineural invasion (PNI)-positive and PNI-negative nerves to fill in these knowledge gaps. The applicability of PN...

A Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Leads to High-Resolution Patient Stratification

Sep 05, 2022

For a study, researchers sought to understand that numerous outcomes and treatment responses have been linked to the characteristics of the genome and transcriptome. The connections between changes in...

An Alpha-Fetoprotein Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

Sep 05, 2022

For a study, researchers sought to examine the on-treatment alpha-fetoprotein (AFP) response as a potential replacement biomarker of prognosis for the combo therapy in an exploratory investigation. Pa...

Prostate Cancer Patients with Castration-Sensitive Androgen Receptor Splice Variant-7 As Biomarkers of Clinical Response

Sep 05, 2022

For a study, researchers sought to look at a variety of strategies to quantify AR-V7 mRNA and protein in prostate cancer cell lines, patient-derived xenograft (PDX) models, publicly available cohorts,...

In Advanced Hepatocellular Carcinoma, Investigate The Biomarkers Caused by Sintilimab Plus IBI305

Sep 05, 2022

For a study, researchers sought to couple baseline blood cytokine measurements using bead-based multiplex immunoassay with multiplex immunofluorescence on tissue specimens to uncover novel markers of ...

Risk Factors for Positive Surgical Margins in Salivary Gland Cancers

Sep 05, 2022

An analysis of patients with salivary gland cancers shows that risk factors for positive surgical margins include age, tumor stage, and treatment center. “Salivary gland cancers are rare mali...

Efficacy of Pembrolizumab Chemotherapy in Gastric Cancer and Tumor Mutational Burden

Sep 02, 2022

For a study, researchers sought to evaluate the impact of tumor mutational burden (TMB) status on the outcomes of first-line pembrolizumab treatment versus chemotherapy in KEYNOTE-062. They investigat...

Efficacy of Anti-PD-1 Antibodies Plus Multikinase Inhibitors in Advanced Gastric Cancer Patients with or Without Liver Metastases

Sep 02, 2022

For a study, researchers sought to examine the combined efficacy results from a phase Ib  regorafenib plus nivolumab (REGONIVO) study and a phase II lenvatinib plus pembrolizumab (LENPEM) trial in ad...